secwatch.observer — SEC 8-K summary
======================================

Issuer:     AMGEN INC (AMGN)
CIK:        0000318154
Form:       8-K
Filed at:   2023-10-06T23:59:59+00:00
Accession:  0001193125-23-252361
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 2.01, 2.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amgen completes $27.8B acquisition of Horizon Therapeutics at $116.50/share
---------------------------------------------------------------------------

- Paid $26.7B cash for Horizon shares; borrowed $4B under term loan to fund portion of consideration.
- Acquisition expected to be accretive to non-GAAP EPS starting in 2024; Amgen to update FY2023 guidance on Q3 call.
- Adds rare-disease drugs TEPEZZA, KRYSTEXXA, UPLIZNA to Amgen's inflammation portfolio.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/318154/000119312523252361/0001193125-23-252361-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/318154/000119312523252361/d534754d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-252361

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer